Xenon Pharmaceuticals (XENE) EBT (2013 - 2026)
Xenon Pharmaceuticals (XENE) reported EBT of -$104.9 million for Q1 2026, down 62.29% year-over-year from -$278.1 million in Q1 2025, and down 142.57% quarter-over-quarter from $246.3 million in Q4 2025.
Xenon Pharmaceuticals (XENE) EBT (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has 14 years of EBT data on file, last reported at -$104.9 million in Q1 2026.
- EBT for Q1 2026 came in at -$104.9 million, down 62.29% year-over-year; the trailing twelve-month figure through Mar 2026 was -$34.1 million (up 86.92% YoY), and the FY2025 annual result was $6.2 million, up 102.54% from the prior year.
- EBT fell to -$104.9 million in Q1 2026 per XENE's latest filing, from $246.3 million in the prior quarter.
- Over five years, EBT peaked at $246.3 million in Q4 2025 and troughed at -$104.9 million in Q1 2026.
- A 5-year average of -$37.5 million and a median of -$47.7 million in 2023 frame the typical range for EBT.
- The sharpest annual moves came in 2022 and 2025: EBT plunged 141.13% in 2022, then jumped 430.55% in 2025.
- A 5-year view of EBT shows it stood at -$32.3 million in 2022, then declined by 13.66% to -$36.8 million in 2023, then plunged by 102.76% to -$74.5 million in 2024, then jumped by 430.55% to $246.3 million in 2025, then plunged by 142.57% to -$104.9 million in 2026.
- Business Quant data shows XENE's EBT at -$104.9 million in Q1 2026, $246.3 million in Q4 2025, and -$90.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 19.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.18 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.31 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Xenon Pharmaceuticals | 4.61 Bn | 4.61 Bn | - | -104.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -104.87 Mn |
| Dec 31, 2025 | 246.34 Mn |
| Sep 30, 2025 | -90.22 Mn |
| Jun 30, 2025 | -85.33 Mn |
| Mar 31, 2025 | -64.62 Mn |
| Dec 31, 2024 | -74.52 Mn |
| Sep 30, 2024 | -63.11 Mn |
| Jun 30, 2024 | -58.26 Mn |
| Mar 31, 2024 | -47.52 Mn |
| Dec 31, 2023 | -36.75 Mn |
| Sep 30, 2023 | -48.62 Mn |
| Jun 30, 2023 | -47.68 Mn |
| Mar 31, 2023 | -41.44 Mn |
| Dec 31, 2022 | -32.34 Mn |
| Sep 30, 2022 | -37.74 Mn |
| Jun 30, 2022 | -31.20 Mn |
| Mar 31, 2022 | -20.06 Mn |
| Dec 31, 2021 | -25.08 Mn |
| Sep 30, 2021 | -15.65 Mn |
| Jun 30, 2021 | -22.33 Mn |